Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.

doi:10.1001/jamanetworkopen.2025.43107

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.

JAMA network open - 3 Nov 2025

Jänne Pasi A, Planchard David, Goto Koichi, Smit Egbert F, de Langen Adrianus Johannes, Goto Yasushi, Ninomiya Kiichiro, Kubo Toshio, Pérol Maurice, Felip Enriqueta, Hayashi Hidetoshi, Nakagawa Kazuhiko, Shimizu Junichi, Nagasaka Misako, Pereira Kaline, Taguchi Ayumi, Ali Ahmed, Karnoub Maha, Yonemochi Rie, Leung David, Li Bob T

Abstract excerpt

Importance: Brain metastases reduce overall survival rates of patients with non-small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])-mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC. Objective: To assess the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Camptothecin

Share to Carcinoma, Non-Small-Cell Lung

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Randomized Controlled Trials as Topic

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 41222935
DOI: 10.1001/jamanetworkopen.2025.43107
PMCID: PMC12612940

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.PMID 41222935Read ↗

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.Semantic proximity Read ↗

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.Semantic proximity Read ↗

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II studySemantic proximity Read ↗

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.Semantic proximity Read ↗

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.Semantic proximity Read ↗

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.Semantic proximity Read ↗

Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.Semantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.